Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in June - Earnings Summary
14/08/2024 14:31
* Sonnet Biotherapeutics Holdings Inc SONN.OQ reported a
quarterly adjusted loss of 70 cents per share for the quarter
ended in June, higher than the same quarter last year, when the
company reported EPS of $-2.86. The mean expectation of
three analysts for the quarter was for a loss of 76 cents per
share. Wall Street expected results to range from -77 cents
to -76 cents per share.
* Reported revenue was zero; analysts expected $28.50
thousand.
* Sonnet Biotherapeutics Holdings Inc's reported EPS for the
quarter was a loss of 70 cents.
* The company reported a quarterly loss of $3.51 million.
* Sonnet Biotherapeutics Holdings Inc shares had fallen
by 24.9%
this quarter and lost 59.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 57.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "strong buy"
Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $30.00
This summary was machine generated from LSEG data August 14 at
01:31 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.76 -0.70 Beat
Mar. 31 2024 0.14 0.07 Missed
Dec. 31 2023 -0.90 -0.31 Beat
Sep. 30 2023 -4.09 -2.09 Beat